The third UCH High Dose Meeting.
The use of high-dose chemotherapy continues to increase in the treatment of a variety of haematological and non-haematological malignancies. At the same time, a greater understanding of haemopoiesis and its regulation has enabled the rapid clinical introduction of a variety of haemopoietic growth factors and peripheral blood stem cell support. Advances in immunology have led to a better understanding of the underlying mechanisms of graft-versus-host disease and the immunology associated with alloBMT. The aim of the UCH High Dose Meeting has been to critically review these advances in light of ongoing and future clinical trials. This report highlights some of the topics discussed.
Chopra
R
R
Department of Haematology, University College London Medical School, UK.
D000046:Academic Medical Centers; D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy; D008131:London / Q000453:epidemiology; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents